# US 2014/0155627 A1 · Process for Forming Amorphous Atorvastatin

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2014/0155627 A1
- Document ID: US20140155627A1
- Status: Published application
- Kind: A1
- Application number: 14/176,081
- Filed: 2014-02-08
- Published: 2014-06-05
- Earliest claimed: 2004-10-28
- Assignees: Pfizer Inc.
- Applicants: Pfizer Inc.
- Inventors: Antone John deBettencourt, III; Peter Robert Rose; Evgenyi Shalaev; George Joseph Quallich; Carl Bernard Ziegler
- Web page: https://patentgrep.com/patent/US20140155627A1

## CPC

- C07D 207/34: with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- A61K 9/145: {with organic compounds}
- A61K 9/146: {with organic macromolecular compounds}
- A61K 9/19: lyophilised {, i.e. freeze-dried, solutions or dispersions (lyophilised products with subsequent particle size reduction A61K9/14; granules or pellets made by lyphilisation A61K9/1682; solid oral dosage forms made by lyophilisation A61K9/2095; lyophilisation additives A61K47/00)}
- A61K 31/40: having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61P 3/06: Antihyperlipidemics
- A61P 19/10: for osteoporosis
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A61P 35/00: Antineoplastic agents
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

A process for forming amorphous atorvastatin comprising the steps of dissolving atorvastatin in a non-hydroxylic solvent and removing the solvent by freeze-drying, as well as processes of dissolving atorvastatin in a hydroxylic solvent with a solubilizing agent or an alkalizing agent or an antioxidant and removing the solvent by freeze-drying to afford amorphous atorvastatin.

## Claims

### Claim 1

(canceled)

### Claim 2

(canceled)

### Claim 3

(canceled)

### Claim 4

(canceled)

### Claim 5

(canceled)

### Claim 6

(canceled)

### Claim 7

(canceled)

### Claim 8

(canceled)

### Claim 9

(canceled)

### Claim 10

(canceled)

### Claim 11

The process for forming amorphous atorvastatin comprising:
(a) dissolving atorvastatin and an antioxidant in a hydroxylic solvent; and
(b) lyophilizing the solution to afford said amorphous atorvastatin.

### Claim 12 (depends on 11)

The process of claim 11 wherein the hydroxylic solvent is selected from the group consisting of: water, an alcohol, and mixture thereof.

### Claim 13 (depends on 11)

The process of claim 11 wherein the antioxidant is selected from the group consisting of: a chelating agent; a free-radical scavenger, and an oxygen scavenger, or mixture thereof.

### Claim 14 (depends on 13)

The process of claim 13 wherein the chelating agent is selected from the group consisting of: a citrate; and ethylenediaminetetraacetic acid.

### Claim 15 (depends on 13)

The process of claim 13 wherein the free-radical scavenger is selected from the group consisting of: butylated hydroxyanisole and butylated hydroxytoluene and wherein the oxygen scavenger is selected from the group consisting of: sodium ascorbate; and potassium ascorbate.
